174 related articles for article (PubMed ID: 35247901)
1. Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
Wei S; Yin D; Yu S; Lin X; Savani MR; Du K; Ku Y; Wu D; Li S; Liu H; Tian M; Chen Y; Bowie M; Hariharan S; Waitkus M; Keir ST; Sugarman ET; Deek RA; Labrie M; Khasraw M; Lu Y; Mills GB; Herlyn M; Wu K; Liu L; Wei Z; Flaherty KT; Abdullah K; Zhang G; Ashley DM
Clin Cancer Res; 2022 May; 28(10):2180-2195. PubMed ID: 35247901
[TBL] [Abstract][Full Text] [Related]
2. A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.
Yu S; Wei S; Savani M; Lin X; Du K; Mender I; Siteni S; Vasilopoulos T; Reitman ZJ; Ku Y; Wu D; Liu H; Tian M; Chen Y; Labrie M; Charbonneau CM; Sugarman E; Bowie M; Hariharan S; Waitkus M; Jiang W; McLendon RE; Pan E; Khasraw M; Walsh KM; Lu Y; Herlyn M; Mills G; Herbig U; Wei Z; Keir ST; Flaherty K; Liu L; Wu K; Shay JW; Abdullah K; Zhang G; Ashley DM
Clin Cancer Res; 2021 Dec; 27(24):6800-6814. PubMed ID: 34593527
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
5. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
6. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
[No Abstract] [Full Text] [Related]
7. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
Hu YH; Jiao BH; Wang CY; Wu JL
CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma.
Di K; Lomeli N; Wood SD; Vanderwal CD; Bota DA
Oncotarget; 2016 Nov; 7(47):77457-77467. PubMed ID: 27764809
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
12. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
14. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
15. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Liu XY; Zhang L; Wu J; Zhou L; Ren YJ; Yang WQ; Ming ZJ; Chen B; Wang J; Zhang Y; Yang JM
PLoS One; 2013; 8(11):e81345. PubMed ID: 24303044
[TBL] [Abstract][Full Text] [Related]
17. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
Li C; Feng S; Chen L
Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Yuan Q; Yang W; Zhang S; Li T; Zuo M; Zhou X; Li J; Li M; Xia X; Chen M; Liu Y
Mol Med; 2021 Jan; 27(1):7. PubMed ID: 33509092
[TBL] [Abstract][Full Text] [Related]
19. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
[TBL] [Abstract][Full Text] [Related]
20. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
Han C; Wang S; Wang H; Zhang J
Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
[No Abstract] [Full Text] [Related]
[Next] [New Search]
